Investors in GSK plc with Losses in Excess of $100K Urged to Act Quickly to Protect Rights in Securities Class Action Lawsuit.

GSK Deadline Alert: Rosen Leading Trial Attorneys Encourages GSK Plc Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit

NEW YORK, April 25, 2025 -- Rosen Law Firm, a global investor rights law firm, reminds investors of the important April 27, 2025 deadline in the securities class action lawsuit filed on behalf of purchasers of GSK Plc (NYSE: GSK) securities between March 3, 2020 and March 2, 2023.

On March 2, 2023, the UK's National Health Service (NHS) announced that it was reviewing its relationship with GSK and other pharmaceutical companies, following allegations of corruption and bribery. On this news, GSK's stock price fell significantly, harming investors.

According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and omissions of material fact about the company's business, operations, and prospects. Specifically, defendants failed to disclose that GSK was aware of the allegations of corruption and bribery, and that the company's relationship with the NHS was under review.

A class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons and entities that purchased GSK securities between March 3, 2020 and March 2, 2023. The lawsuit seeks to recover damages for GSK investors under the federal securities laws.

Rosen Law Firm is preparing a securities lawsuit on behalf of those who purchased GSK securities during the Class Period. If you purchased GSK securities during the Class Period and suffered a loss, you may be entitled to join this action and recover your investment losses. Please contact our offices at 212-307-1030 or [email address] to learn more about this action and your rights as an investor.

To join this action, simply email [email address] or call toll-free at 212-307-1030. You can also follow us on Twitter - @RosenLawFirm - for updates on the case. A case is not approved until an investor has retained one of our attorneys in an initial consultation.

Rosen Law Firm represents investors worldwide, focusing exclusively on securities law litigation. If you are a GSK investor and would like to join the action, please contact us at [email address] or 212-307-1030. You can also follow us on Twitter - @RosenLawFirm - for updates on the case.